What James Lind would ask us on Clinical Trials Day

On May 20, 1747, aboard HMS Salisbury, Scottish naval surgeon James Lind divided twelve sailors with scurvy into six pairs and gave each pair a different treatment. The citrus group recovered fastest, creating one of the earliest controlled comparisons in clinical research. The trial was meant to run for fourteen days. It ended on day six, when the ship ran out of citrus. By then, the two sailors who had been given oranges and lemons were already recovering. None of the others were. Lind had run the first controlled clinical trial in history. He had also done something quieter and more radical: he had refused to accept the prevailing status quo on a disease that was killing more sailors than enemy action.

Clinical Trials Day commemorates that trial. It is usually a day for gratitude, and rightly so. Trials do not happen without participants, sites, coordinators, investigators, and the unglamorous labor of people who keep complex studies running. They deserve thanks.

But gratitude on its own is a low bar. The harder, more useful question on Clinical Trials Day is whether the way we run trials in 2026 is worthy of the people who make them possible.

We named our company after Lind because we think the honest answer is: not yet.

Lind's question to the Royal Navy was about the method. Given a disease killing more sailors than enemy action, was the standard treatment the best one available? Asked of us today, the equivalent question is about the operating model. Given what trials are meant to do, is the one we have built good enough?

The asymmetry, acknowledged

Lind's trial was small, local, and free from the complexity modern clinical research rightly carries. He worked with twelve patients, one site, one investigator, and no regulatory framework to speak of. Modern trials operate under constraints that did not exist in 1747: protocol complexity, multi-region regulation, data integrity standards, and patient safety oversight. Those constraints are real, and many are necessary. The problem is what happens when necessary complexity is compounded by avoidable fragmentation, unclear ownership, and incentives that are not aligned to delivery.

Lind’s discipline is worth carrying forward: a clear question, a controlled comparison, and accountability for reaching an answer. That discipline scales. In modern trials, it is also easy to lose.

Where trials go wrong

When a trial misses its timeline, the conversation usually starts with enrollment. Recruitment was harder than expected. Patients were not where the protocol assumed they would be.

These are real problems, but they are usually symptoms. The structural failure tends to happen earlier, when timelines, feasibility assumptions, and operational ownership are first set.

Sponsors are routinely sold timelines that look plausible in a slide deck but are not backed by an operating model accountable for delivering them. Feasibility work is shallow. Site selection is optimistic. Patient flow assumptions are inherited from a prior indication or borrowed from a database that does not reflect the protocol on the table. Operational ownership is split among a primary CRO, specialty vendors, and the sponsor's internal teams, each with different incentives and definitions of success.

By the time enrollment is visibly off track, the trial may already have drifted from the assumptions set at the start. Timelines, feasibility, and operational ownership have to be built together for the target to hold.

This is the accountability gap. It is not a problem of effort. The people running these trials work hard. It is a problem of structure: the way trials are scoped, contracted, staffed, and governed makes it nearly impossible for any single party to be accountable for delivery from protocol through database lock.

What participants pay

Operational failure is often discussed as a sponsor cost. It is also a participant cost.

Avoidable delays are time participants have given to a trial that did not respect their time in return. Rescreens are visits that should not have been needed. Protocol amendments that should have been caught at feasibility become changes communicated downstream to people who agreed to one set of expectations and are now living with another. Site friction and operational drag are not abstract inefficiencies. They are paid for by the people the trial exists to serve.

Respect for participants shows up in how a trial is run: protocols that can be executed, feasibility grounded in real site and patient data, and timelines treated as operational responsibilities rather than planning assumptions.

The accountable answer

The Accountable Research Organization (ARO) model is how Lindus closes the gap.

In practice, that starts with how the work is structured. Lindus uses performance-based contracts with milestone-based payments, aligning the commercial model to trial progress rather than hours worked.

The distinction matters. In traditional CRO models, timelines, scope, and responsibility can drift apart as a study changes. The ARO model is engineered to keep them connected: milestones are agreed upfront, delivery is owned by one integrated team, and progress is tied to outcomes rather than activity.

Feasibility is anchored in operational reality rather than in marketing assumptions, so the timeline in the proposal is one the delivery team has built and committed to run. The work runs on Citrus, our AI-native trial operating system, which integrates the data, workflows, and visibility a single accountable team needs to operate against the plan.

Across Lindus-executed trials, 82% completed enrollment on or ahead of the enrollment time presented at proposal. The result reflects how the work is structured: feasibility informs the timeline, the delivery model is built around that commitment, and one accountable team owns execution.

The harder question

The Royal Navy took another forty years to act on Lind’s findings, and scurvy continued to kill sailors long after his trial was published. His contribution was a method and a refusal to accept that the way things had always been done was the way they had to remain.

What James Lind would ask us on Clinical Trials Day is whether the systems we have built are worthy of the participants, sites, investigators, and teams who make clinical research possible.

We do not think they are yet, but we know they can be.

‍